Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
TORRENT PHARMA TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
TORRENT PHARMA Mar-23 |
TEVA PHARMA Dec-13 |
TORRENT PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,723 | 3,459 | - | |
Low | Rs | 1,243 | 3,005 | - | |
Sales per share (Unadj.) | Rs | 284.2 | 1,985.4 | - | |
Earnings per share (Unadj.) | Rs | 36.8 | 124.0 | - | |
Cash flow per share (Unadj.) | Rs | 57.7 | 284.5 | - | |
Dividends per share (Unadj.) | Rs | 22.00 | 108.57 | - | |
Avg Dividend yield | % | 1.5 | 3.4 | 44.2% | |
Book value per share (Unadj.) | Rs | 183.1 | 2,205.4 | - | |
Shares outstanding (eoy) | m | 338.45 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.2 | 1.6 | 320.4% | |
Avg P/E ratio | x | 40.3 | 26.1 | 154.6% | |
P/CF ratio (eoy) | x | 25.7 | 11.4 | 226.3% | |
Price / Book Value ratio | x | 8.1 | 1.5 | 552.4% | |
Dividend payout | % | 59.8 | 87.5 | 68.3% | |
Avg Mkt Cap | Rs m | 501,779 | 2,741,007 | 18.3% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 16,777 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,459.7 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,340.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 96,202 | 1,683,624 | 5.7% | |
Other income | Rs m | 632 | 0 | - | |
Total revenues | Rs m | 96,834 | 1,683,624 | 5.8% | |
Gross profit | Rs m | 28,240 | 461,061 | 6.1% | |
Depreciation | Rs m | 7,066 | 136,089 | 5.2% | |
Interest | Rs m | 3,334 | 33,069 | 10.1% | |
Profit before tax | Rs m | 18,472 | 291,903 | 6.3% | |
Minority Interest | Rs m | 0 | 1,326 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -191,619 | -0.0% | |
Tax | Rs m | 6,019 | -3,564 | -168.9% | |
Profit after tax | Rs m | 12,452 | 105,175 | 11.8% | |
Gross profit margin | % | 29.4 | 27.4 | 107.2% | |
Effective tax rate | % | 32.6 | -1.2 | -2,669.1% | |
Net profit margin | % | 12.9 | 6.2 | 207.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 53,137 | 1,137,114 | 4.7% | |
Current liabilities | Rs m | 54,473 | 991,659 | 5.5% | |
Net working cap to sales | % | -1.4 | 8.6 | -16.1% | |
Current ratio | x | 1.0 | 1.1 | 85.1% | |
Inventory Days | Days | 15 | 91 | 17.1% | |
Debtors Days | Days | 7 | 96 | 7.7% | |
Net fixed assets | Rs m | 91,390 | 549,909 | 16.6% | |
Share capital | Rs m | 1,692 | 4,144 | 40.8% | |
Net worth | Rs m | 61,981 | 1,870,187 | 3.3% | |
Long term debt | Rs m | 24,962 | 860,875 | 2.9% | |
Total assets | Rs m | 144,682 | 3,847,621 | 3.8% | |
Interest coverage | x | 6.5 | 9.8 | 66.5% | |
Debt to equity ratio | x | 0.4 | 0.5 | 87.5% | |
Sales to assets ratio | x | 0.7 | 0.4 | 152.0% | |
Return on assets | % | 10.9 | 3.6 | 303.7% | |
Return on equity | % | 20.1 | 5.6 | 357.2% | |
Return on capital | % | 25.1 | 4.9 | 508.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 23,681 | 268,283 | 8.8% | |
From Investments | Rs m | -24,153 | -95,063 | 25.4% | |
From Financial Activity | Rs m | 774 | -321,823 | -0.2% | |
Net Cashflow | Rs m | 1,101 | -148,604 | -0.7% |
Compare TORRENT PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare TORRENT PHARMA With: ABBOTT INDIA ELDER PHARMA BAFNA PHARMA SANOFI INDIA NEULAND LABS
On Monday, Indian share markets reversed the trend as the session progressed and ended the day higher.